A quantitative study to assess synergistic interactions between urotensin II and angiotensin II

European Journal of Pharmacology

Volumn 586, Issue 1-3, 2008, Pages 350-351

  Lamarre, Neil S ^a   Tallarida, Ronald J ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Response surface; Synergism; Urotensin II

Indexed keywords

ANGIOTENSIN II; UROTENSIN II;

ADVENTITIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; QUANTITATIVE STUDY; RAT; RESPONSE SURFACE METHOD; VASCULAR ENDOTHELIUM; VASCULAR RING;

ANGIOTENSIN II; ANIMALS; AORTA, THORACIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; MALE; MUSCLE, SMOOTH, VASCULAR; POTASSIUM CHLORIDE; RATS; RATS, SPRAGUE-DAWLEY; UROTENSINS; VASOCONSTRICTOR AGENTS;

EID: 43549109808     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.02.071     Document Type: Article

References (7)

1. Bohm F., and Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br. J. Pharmacol. 135 (2002) 25-27
2. Douglas S.A., and Ohlstein E.H. Human urotensin II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc. Med. 10 (2000) 229-237
3. Grabovsky Y., and Tallarida R.J. Isobolographic analysis for combinations of a full and partial agonist: curved isoboles. J. Pharmacol. Exp Ther. 310 (2004) 981-986
4. Kuttan S.C., and Sim M.K. Angiotensin II-induced tachyphylaxis in aortas of normo- and hypertensive rats: changes in receptor affinity. Eur. J. Pharmacol. 232 (1993) 173-180
5. Tallarida R.J. Drug Synergism and Dose-effect Data Analysis (2000), Chapman and Hall/CRC Press, Boca Raton, FL
6. Tallarida R.J. An overview of drug combination analysis with isobolograms (perspectives in pharmacology). J. Pharmacol. Exp. Ther. 319 (2006) 1-7
7. Tallarida R.J. Interactions between drugs and occupied receptors. J. Pharmacol. Exp. Ther. 113 (2007) 197-209